Enzymes involved in metabolism of extracellular nucleotides and nucleosides: Functional implications and measurement of activities

Critical Reviews in Biochemistry and Molecular Biology

Volumn 49, Issue 6, 2014, Pages 473-497

  Yegutkin, Gennady G ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Adenosine deaminase; Ecto 5 nucleotidase CD73; Ecto nucleotide kinases; Enzymatic assays; NTPDase; Purinergic signaling

Indexed keywords

5' NUCLEOTIDASE; ACID PHOSPHATASE; ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ALKALINE PHOSPHATASE; ECTO 5' NUCLEOTIDASE; ECTO NUCLEOTIDASE; ENZYME; LUCIFERASE; LUCIFERIN; NDPK ENZYME; NME ENZYME; NPP ENZYME; NTPDASE ENZYME; NUCLEOSIDE; NUCLEOSIDE DIPHOSPHATE KINASE NM23; NUCLEOTIDASE; NUCLEOTIDE; PHOSPHATE; PHOSPHORUS 32; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PURINE; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; ECTOATPASE; INORGANIC PYROPHOSPHATASE; NUCLEOSIDE DIPHOSPHATE KINASE;

ARTERY CALCIFICATION; BIOLUMINESCENCE; CAPILLARY ELECTROPHORESIS; CARCINOGENESIS; CYTOCHEMISTRY; ELECTROCHEMICAL ENZYME COUPLED ASSAY; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CYTOCHEMISTRY; ENZYME METABOLISM; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOCHEMISTRY; HUMAN; IMMUNOMODULATION; INFLAMMATION; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; P I LIBERATING ASSAY; PROTEIN EXPRESSION; PURINE METABOLISM; REVIEW; SPECTROPHOTOMETRY; THIN LAYER CHROMATOGRAPHY; TISSUE DISTRIBUTION; TISSUE STRUCTURE; ANIMAL; ENZYME ASSAY; METABOLISM; PROCEDURES;

5'-NUCLEOTIDASE; ADENOSINE DEAMINASE; ADENOSINE TRIPHOSPHATASES; ANIMALS; ENZYME ASSAYS; HUMANS; NUCLEOSIDE-DIPHOSPHATE KINASE; NUCLEOSIDES; NUCLEOTIDASES; NUCLEOTIDES; PYROPHOSPHATASES;

EID: 84912096578     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2014.953627     Document Type: Review

References (260)

1. Abate N, Chandalia M, Di Paola R, et al. (2006). Mechanisms of disease: ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors. Nat Clin Pract Endocrinol Metab 2:694-701.
2. Abbracchio MP, Burnstock G, Boeynaems JM, et al. (2006). International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281-341.
3. Abbracchio MP, Burnstock G, Verkhratsky A, et al. (2009). Purinergic signalling in the nervous system: an overview. Trends Neurosci 32: 19-29.
4. Airas L, Niemela J, Salmi M, et al. (1997). Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J Cell Biol 136:421-31.
5. Aiuti A, Cattaneo F, Galimberti S, et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360:447-58.
6. Al-Rashida M, Iqbal J. (2014). Therapeutic potentials of ecto-nucleoside triphosphate diphosphohydrolase, ecto-nucleotide pyrophosphatase/ phosphodiesterase, ecto-50-nucleotidase, and alkaline phosphatase inhibitors. Med Res Rev 34:703-43.
7. Albright RA, Chang WC, Robert D, et al. (2012). NPP4 is a procoagulant enzyme on the surface of vascular endothelium. Blood 120:4432-40.
8. Albright RA, Ornstein DL, Cao W, et al. (2014). The molecular basis of purinergic signal metabolism by ecto-nucleotide pyrophosphatase/ phosphodiesterases 4 and 1 and implications in stroke. J Biol Chem 289:3294-306.
9. Algars A, Karikoski M, Yegutkin GG, et al. (2011). Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood 117:4387-93.
10. Aliagas E, Vidal A, Torrejon-Escribano B, et al. (2013). Ectonucleotidases distribution in human cyclic and postmenopausic endometrium. Purinergic Signal 9:227-37.
11. Anderson HC, Harmey D, Camacho NP, et al. (2005). Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol 166:1711-20.
12. Antonioli L, Colucci R, La Motta C, et al. (2012). Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets 13: 842-62.
13. Antonioli L, Pacher P, Vizi ES, et al. (2013). CD39 and CD73 in immunity and inflammation. Trends Mol Med 19:355-67.
14. Arakaki N, Nagao T, Niki R, et al. (2003). Possible role of cell surface H+-ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol Cancer Res 1:931-9.
15. Araujo CL, Quintero IB, Kipar A, et al. (2014). Prostatic acid phosphatase is the main acid phosphatase with 50-ectonucleotidase activity in the male mouse saliva and regulates salivation. Am J Physiol Cell Physiol 306:C1017-27.
16. Arpaia E, Benveniste P, Di Cristofano A, et al. (2000). Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 191:2197-208.
17. Bai Z, Cai L, Umemoto E, et al. (2013). Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol 190: 2036-48.
18. Banz Y, Beldi G, Wu Y, et al. (2008). CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol 142:627-37.
19. Bartel DL, Sullivan SL, Lavoie EG, et al. (2006). Nucleoside triphosphate diphosphohydrolase-2 is the ecto-ATPase of type I cells in taste buds. J Comp Neurol 497:1-12.
20. Bastid J, Cottalorda-Regairaz A, Alberici G, et al. (2012). ENTPD1/ CD39 is a promising therapeutic target in oncology. Oncogene 32: 1743-51.
21. Bavaresco L, Bernardi A, Braganhol E, et al. (2008). The role of ecto-50- nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem 319:61-8.
22. Baykov AA, Evtushenko OA, Avaeva SM. (1988). A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Anal Biochem 171:266-70.
23. Beigi R, Kobatake E, Aizawa M, et al. (1999). Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol 276:C267-78.
24. Belcher SM, Zsarnovszky A, Crawford PA, et al. (2006). Immunolocalization of ecto-nucleoside triphosphate diphosphohydrolase 3 in rat brain: implications for modulation of multiple homeostatic systems including feeding and sleep-wake behaviors. Neuroscience 137:1331-46.
25. Bellingan G, Maksimow M, Howell DC, et al. (2014). The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2:98-107.
26. Bertrand A, Buret J. (1982). A one-step determination of serum 50-nucleotidase using a centrifugal analyzer. Clin Chim Acta 119: 275-84.
27. Bilitou A, Watson J, Gartner A, et al. (2009). The NM23 family in development. Mol Cell Biochem 329:17-33.
28. Blackburn MR, Datta SK, Kellems RE. (1998). Adenosine deaminasedeficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273: 5093-100.
29. Blackburn MR, Kellems RE. (2005). Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 86:1-41.
30. Blackburn MR, Volmer JB, Thrasher JL, et al. (2000). Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med 192:159-70.
31. Boison D. (2013). Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev 65:906-43.
32. Boissan M, Lacombe ML. (2011). Learning about the functions of NME/ NM23: lessons from knockout mice to silencing strategies. Naunyn Schmiedebergs Arch Pharmacol 384:421-31.
33. Bonner F, Borg N, Jacoby C, et al. (2013). Ecto-50-nucleotidase on immune cells protects from adverse cardiac remodeling. Circ Res 113: 301-12.
34. Boring YC, Flogel U, Jacoby C, et al. (2013). Lack of ecto-50-nucleotidase (CD73) promotes arteriogenesis. Cardiovasc Res 97:88-96.
35. Bours MJL, Swennen ELR, Di Virgilio F, et al. (2006). Adenosine 50- triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112:358-404.
36. Braun N, Sevigny J, Robson SC, et al. (2000). Assignment of ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to microglia and vasculature of the brain. Eur J Neurosci 12: 4357-66.
37. Braun N, Sevigny J, Robson SC, et al. (2004). Association of the ecto- ATPase NTPDase2 with glial cells of the peripheral nervous system. Glia 45:124-32.
38. Buchheiser A, Ebner A, Burghoff S, et al. (2011). Inactivation of CD73 promotes atherogenesis in apolipoprotein E-deficient mice. Cardiovasc Res 92:338-47.
39. Burnstock G, Ralevic V. (2014). Purinergic signaling and blood vessels in health and disease. Pharmacol Rev 66:102-92.
40. Burrell HE, Wlodarski B, Foster BJ, et al. (2005). Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface. J Biol Chem 280:29667-76.
41. Buxton IL, Kaiser RA, Oxhorn BC, et al. (2001). Evidence supporting the Nucleotide Axis Hypothesis: ATP release and metabolism by coronary endothelium. Am J Physiol Heart Circ Physiol 281: H1657-66.
42. Buxton IL, Yokdang N, Matz RM. (2010). Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. Cancer Lett 291:131-41.
43. Camici M, Micheli V, Ipata PL, et al. (2010). Pediatric neurological syndromes and inborn errors of purine metabolism. Neurochem Int 56:367-78.
44. Cardenal A, Masuda I, Haas AL, et al. (1996). Identification of a nucleotide pyrophosphohydrolase from articular tissues in human serum. Arthritis Rheum 39:252-6.
45. Champagne E, Martinez LO, Collet X, et al. (2006). Ecto-F1Fo ATP synthase/F1 ATPase: metabolic and immunological functions. Curr Opin Lipidol 17:279-84.
46. Chao TY, Wu YY, Janckila AJ. (2010). Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. Clin Chim Acta 411:1553-64.
47. Chen BC, Lee CM, Lin WW. (1996). Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. Br J Pharmacol 119:1628-34.
48. Chen JF, Eltzschig HK, Fredholm BB. (2013). Adenosine receptors as drug targets-what are the challenges?. Nat Rev Drug Discov 12: 265-86.
49. Clair T, Lee HY, Liotta LA, et al. (1997). Autotaxin is an exoenzyme possessing 50-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities. J Biol Chem 272:996-1001.
50. Clayton A, Al-Taei S, Webber J, et al. (2011). Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 187:676-83.
51. Coade SB, Pearson JD. (1989). Metabolism of adenine nucleotides in human blood. Circ Res 65:531-7.
52. Coddou C, Yan Z, Obsil T, et al. (2011). Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63:641-83.
53. Cohen A, Grunebaum E, Arpaia E, et al. (2000). Immunodeficiency caused by purine nucleoside phosphorylase deficiency. In: Roifman CM, ed. Immunology and allergy clinics of North America. Philadelphia (PA): WB Saunders Company, 143-59.
54. Colgan SP, Eltzschig HK, Eckle T, et al. (2006). Physiological roles for ecto-50-nucleotidase (CD73). Purinergic Signal 2:351-60.
55. Corriden R, Insel PA. (2010). Basal release of ATP: an autocrineparacrine mechanism for cell regulation. Sci Signal 3:re1.
56. Crack BE, Pollard CE, Beukers MW, et al. (1995). Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol 114:475-81.
57. Dale N, Frenguelli BG. (2012). Measurement of purine release with microelectrode biosensors. Purinergic Signal 8:27-40.
58. DePierre JW, Karnovsky ML. (1974a). Ecto-enzyme of granulocytes: 50-nucleotidase. Science 183:1096-8.
59. DePierre JW, Karnovsky ML. (1974b). Ecto-enzymes of the guinea pig polymorphonuclear leukocyte. I. Evidence for an ecto-adenosine monophosphatase, adenosine triphosphatase, and -p-nitrophenyl phosphates. J Biol Chem 249:7111-20.
60. Devenish RJ, Prescott M, Rodgers AJ. (2008). The structure and function of mitochondrial F1F0-ATP synthases. Int Rev Cell Mol Biol 267: 1-58.
61. Donaldson SH, Picher M, Boucher RC. (2002). Secreted and cellassociated adenylate kinase and nucleoside diphosphokinase contribute to extracellular nucleotide metabolism on human airway surfaces. Am J Respir Cell Mol Biol 26:209-15.
62. Dwyer KM, Robson SC, Nandurkar HH, et al. (2004). Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 113:1440-6.
63. Dzeja P, Terzic A. (2009). Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci 10:1729-72.
64. Dzeja PP, Chung S, Terzic A. (2007). Integration of adenylate kinase, glycolytic and glycogenolytic circuits in cellular energetics. In: Saks V, ed. Molecular system bioenergetics. Weinheim: Wiley-VCH, 265-302.
65. Eckle T, Fullbier L, Wehrmann M, et al. (2007a). Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol 178:8127-37.
66. Eckle T, Krahn T, Grenz A, et al. (2007b). Cardioprotection by ecto-50- nucleotidase (CD73) and A2B adenosine receptors. Circulation 115: 1581-90.
67. El-Tayeb A, Iqbal J, Behrenswerth A, et al. (2009). Nucleoside-50- monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-50-nucleotidase. J Med Chem 52:7669-77.
68. Elkan PN, Pierce SB, Segel R, et al. (2014). Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921-31.
69. Eltzschig HK, Sitkovsky MV, Robson SC. (2012). Purinergic signaling during inflammation. N Engl J Med 367:2322-33.
70. Enjyoji K, Sevigny J, Lin Y, et al. (1999). Targeted disruption of cd39/ ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5:1010-17.
71. Erlinge D, Burnstock G. (2008). P2 receptors in cardiovascular regulation and disease. Purinergic Signal 4:1-20.
72. Fabre ACS, Vantourout P, Champagne E, et al. (2006). Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y(13)- mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 63:2829-37.
73. Fan H, Tansi FL, Weihofen WA, et al. (2012). Molecular mechanism and structural basis of interactions of dipeptidyl peptidase IV with adenosine deaminase and human immunodeficiency virus type-1 transcription transactivator. Eur J Cell Biol 91:265-73.
74. Fan Y, Scriba GK. (2010). Advances in capillary electrophoretic enzyme assays. J Pharm Biomed Anal 53:1076-90.
75. Fausther M, Lecka J, Kukulski F, et al. (2007). Cloning, purification, and identification of the liver canalicular ecto-ATPase as NTPDase8. Am J Physiol Gastrointest Liver Physiol 292:G785-95.
76. Fausther M, Lecka J, Soliman E, et al. (2012). Coexpression of ecto-50- nucleotidase/CD73 with specific NTPDases differentially regulates adenosine formation in the rat liver. Am J Physiol Gastrointest Liver Physiol 302:G447-59.
77. Feng L, Sun X, Csizmadia E, et al. (2011). Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 13:206-16.
78. Fiske CH, Subbarow Y. (1925). The colorimetric determination of phosphorus. J Biol Chem 66:375-400.
79. Flogel U, Burghoff S, van Lent PL, et al. (2012). Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci Transl Med 4:146ra108.
80. Franco R, Pacheco R, Gatell JM, et al. (2007). Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit Rev Immunol 27:495-509.
81. Fredholm BB, AP IJ, Jacobson KA, et al. (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63:1-34.
82. Freundlieb M, Zimmermann H, Muller CE. (2013). A new, sensitive ecto-50-nucleotidase assay for compound screening. Anal Biochem 446C:53-8.
83. Friedman DJ, Kunzli BM, YI AR, et al. (2009). From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci USA 106:16788-93.
84. Frittitta L, Camastra S, Baratta R, et al. (1999). A soluble PC-1 circulates in human plasma: relationship with insulin resistance and associated abnormalities. J Clin Endocrinol Metab 84:3620-5.
85. Fu Y, Hou Y, Fu C, et al. (2011). A novel mechanism of gamma/delta T-lymphocyte and endothelial activation by shear stress: the role of ecto-ATP synthase beta chain. Circ Res 108:410-17.
86. Gan XT, Taniai S, Zhao G, et al. (2014). CD73-TNAP crosstalk regulates the hypertrophic response and cardiomyocyte calcification due to alpha1 adrenoceptor activation. Mol Cell Biochem 394:237-46.
87. Gardiner DG. (1979). A rapid and sensitive fluorimetric assay for adenosine, inosine, and hypoxanthine. Anal Biochem 95:377-82.
88. Gijsbers R, Aoki J, Arai H, et al. (2003). The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett 538:60-4.
89. Giuliani P, Ballerini P, Ciccarelli R, et al. (2012). Tissue distribution and metabolism of guanosine in rats following intraperitoneal injection. J Biol Regul Homeost Agents 26:51-65.
90. Goding JW, Grobben B, Slegers H. (2003). Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/ phosphodiesterase family. Biochim Biophys Acta 1638:1-19.
91. Goepfert C, Sundberg C, Sevigny J, et al. (2001). Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 104: 3109-15.
92. Gordon EL, Pearson JD, Slakey LL. (1986). The hydrolysis of extracellular adenine nucleotides by cultured endothelial cells from pig aorta. Feed-forward inhibition of adenosine production at the cell surface. J Biol Chem 261:15496-507.
93. Grenz A, Zhang H, Hermes M, et al. (2007). Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 21:2863-73.
94. Grobben B, Anciaux K, Roymans D, et al. (1999). An ecto-nucleotide pyrophosphatase is one of the main enzymes involved in the extracellular metabolism of ATP in rat C6 glioma. J Neurochem 72: 826-34.
95. Guzman-Aranguez A, Santano C, Martin-Gil A, et al. (2013). Nucleotides in the eye: focus on functional aspects and therapeutic perspectives. J Pharmacol Exp Ther 345:331-41.
96. Hasegawa T, Bouis D, Liao H, et al. (2008). Ecto-50 nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathy. Circ Res 103:1410-21.
97. Hassan A, Booth C, Brightwell A, et al. (2012). Outcome of hematopoietic stem cell transplantation for adenosine deaminasedeficient severe combined immunodeficiency. Blood 120:3615-24; quiz 26.
98. Hayman AR, Jones SJ, Boyde A, et al. (1996). Mice lacking tartrateresistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 122:3151-62.
99. Helenius M, Jalkanen S, Yegutkin GG. (2012). Enzyme-coupled assays for simultaneous detection of nanomolar ATP, ADP, AMP, adenosine, inosine and pyrophosphate concentrations in extracellular fluids. Biochim Biophys Acta 1823:1967-75.
100. Henttinen T, Jalkanen S, Yegutkin GG. (2003). Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by Ecto-50-nucleotidase/CD73-dependent mechanism. J Biol Chem 278:24888-95.
101. Hessle L, Johnson KA, Anderson HC, et al. (2002). Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99:9445-9.
102. Heuts DP, Weissenborn MJ, Olkhov RV, et al. (2012). Crystal structure of a soluble form of human CD73 with ecto-50-nucleotidase activity. Chembiochem 13:2384-91.
103. Houben AJ, Moolenaar WH. (2011). Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 30:557-65.
104. Hunsucker SA, Mitchell BS, Spychala J. (2005). The 50-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 107: 1-30.
105. Idzko M, Ferrari D, Eltzschig HK. (2014). Nucleotide signalling during inflammation. Nature 509:310-17.
106. Ipata PL. (2011). Origin, utilization, and recycling of nucleosides in the central nervous system. Adv Physiol Educ 35:342-6.
107. Iqbal J, Levesque SA, Sevigny J, et al. (2008a). A highly sensitive CEUV method with dynamic coating of silica-fused capillaries for monitoring of nucleotide pyrophosphatase/phosphodiesterase reactions. Electrophoresis 29:3685-93.
108. Iqbal J, Jirovsky D, Lee SY, et al. (2008b). Capillary electrophoresisbased nanoscale assays for monitoring ecto-50-nucleotidase activity and inhibition in preparations of recombinant enzyme and melanoma cell membranes. Anal Biochem 373:129-40.
109. Iqbal J, Muller CE. (2011). High-sensitivity capillary electrophoresis method for monitoring purine nucleoside phosphorylase and adenosine deaminase reactions by a reversed electrode polarity switching mode. J Chromatogr A 1218:4764-71.
110. Iqbal J, Vollmayer P, Braun N, et al. (2005). A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction. Purinergic Signal 1:349-58.
111. Jackson SW, Hoshi T, Wu Y, et al. (2007). Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol 171:1395-404.
112. Jacobson KA, Gao ZG. (2006). Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-64.
113. Jansen S, Perrakis A, Ulens C, et al. (2012). Structure of NPP1, an ectonucleotide pyrophosphatase/phosphodiesterase involved in tissue calcification. Structure 20:1948-59.
114. Janssen E, Dzeja PP, Oerlemans F, et al. (2000). Adenylate kinase 1 gene deletion disrupts muscle energetic economy despite metabolic rearrangement. EMBO J 19:6371-81.
115. Joseph SM, Buchakjian MR, Dubyak GR. (2003). Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes. J Biol Chem 278:23331-42.
116. Junger WG. (2012). Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 11:201-12.
117. Kaczmarek E, Koziak K, Sevigny J, et al. (1996). Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271:33116-22.
118. Kalckar HM, Plesner P. (1956). Enzymic micro determinations of uric acid, hypoxanthine, xanthine, adenine, and xanthopterine by ultraviolet spectrophotometry. Methods Biochem Anal 3:97-110.
119. Kanda H, Newton R, Klein R, et al. (2008). Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 9:415-23.
120. Kather H, Wieland E, Waas W. (1987). Chemiluminescent determination of adenosine, inosine, and hypoxanthine/xanthine. Anal Biochem 163: 45-51.
121. Kauffenstein G, Drouin A, Thorin-Trescases N, et al. (2010). NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 85:204-13.
122. Kaunitz JD, Yamaguchi DT. (2008). TNAP, TrAP, ecto-purinergic signaling, and bone remodeling. J Cell Biochem 105:655-62.
123. Kim H, Lee HJ, Oh Y, et al. (2014). The DUSP26 phosphatase activator adenylate kinase 2 regulates FADD phosphorylation and cell growth. Nat Commun 5:3351.
124. Kirino M, Parnes J, Hansen A, et al. (2013). Evolutionary origins of taste buds: phylogenetic analysis of purinergic neurotransmission in epithelial chemosensors. Open Biol 3:130015.
125. Kishore BK, Isaac J, Fausther M, et al. (2005). Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling. Am J Physiol Renal Physiol 288:F1032-43.
126. Kiss J, Yegutkin GG, Koskinen K, et al. (2007). IFN-beta protects from vascular leakage via up-regulation of CD73. Eur J Immunol 37: 3334-8.
127. Kittel A, Csapo ZS, Csizmadia E, et al. (2004a). Co-localization of P2Y1 receptor and NTPDase1/CD39 within caveolae in human placenta. Eur J Histochem 48:253-9.
128. Kittel A, Pelletier J, Bigonnesse F, et al. (2004b). Localization of nucleoside triphosphate diphosphohydrolase-1 (NTPDase1) and NTPDase2 in pancreas and salivary gland. J Histochem Cytochem 52:861-71.
129. Knapp K, Zebisch M, Pippel J, et al. (2012). Crystal structure of the human ecto-50-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure 20:2161-73.
130. Knowles AF. (2011). The GDA1-CD39 superfamily: NTPDases with diverse functions. Purinergic Signal 7:21-45.
131. Kohler D, Eckle T, Faigle M, et al. (2007). CD39/Ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116:1784-94.
132. Koszalka P, Ozuyaman B, Huo Y, et al. (2004). Targeted disruption of cd73/ecto-50-nucleotidase alters thromboregulation and augments vascular inflammatory response [see comment]. Circ Res 95: 814-21.
133. Kukulski F, Levesque SA, Lavoie EG, et al. (2005). Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 1:193-204.
134. Kukulski F, Levesque SA, Sevigny J. (2011). Impact of ectoenzymes on P2 and P1 receptor signaling. Adv Pharmacol 61:263-99.
135. Kusu T, Kayama H, Kinoshita M, et al. (2013). Ecto-nucleoside triphosphate diphosphohydrolase 7 controls Th17 cell responses through regulation of luminal ATP in the small intestine. J Immunol 190:774-83.
136. Lacombe ML, Milon L, Munier A, et al. (2000). The human Nm23/ nucleoside diphosphate kinases. J Bioenerg Biomembr 32:247-58.
137. Lalles JP. (2014). Intestinal alkaline phosphatase: novel functions and protective effects. Nutr Rev 72:82-94.
138. Langer D, Hammer K, Koszalka P, et al. (2008). Distribution of ectonucleotidases in the rodent brain revisited. Cell Tissue Res 334: 199-217.
139. Langer D, Ikehara Y, Takebayashi H, et al. (2007). The ectonucleotidases alkaline phosphatase and nucleoside triphosphate diphosphohydrolase 2 are associated with subsets of progenitor cell populations in the mouse embryonic, postnatal and adult neurogenic zones. Neuroscience 150:863-79.
140. Lanzetta PA, Alvarez LJ, Reinach PS, et al. (1979). An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem 100: 95-7.
141. Lavoie EG, Fausther M, Kauffenstein G, et al. (2010). Identification of the ectonucleotidases expressed in mouse, rat, and human Langerhans islets: potential role of NTPDase3 in insulin secretion. Am J Physiol Endocrinol Metab 299:E647-56.
142. Lavoie EG, Gulbransen BD, Martin-Satue M, et al. (2011). Ectonucleotidases in the digestive system: focus on NTPDase3 localization. Am J Physiol Gastrointest Liver Physiol 300:G608-20.
143. Lazarowski ER. (2012). Vesicular and conductive mechanisms of nucleotide release. Purinergic Signal 8:359-73.
144. Lazarowski ER, Boucher RC, Harden TK. (2000). Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J Biol Chem 275:31061-8.
145. Lazarowski ER, Homolya L, Boucher RC, et al. (1997). Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J Biol Chem 272:20402-7.
146. Lazarowski ER, Tarran R, Grubb BR, et al. (2004). Nucleotide release provides a mechanism for airway surface liquid homeostasis. J Biol Chem 279:36855-64.
147. Lee HJ, Pyo JO, Oh Y, et al. (2007). AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. Nat Cell Biol 9:1303-10.
148. Lee SY, Levesque SA, Sevigny J, et al. (2012). A highly sensitive capillary electrophoresis method using p-nitrophenyl 50-thymidine monophosphate as a substrate for the monitoring of nucleotide pyrophosphatase/phosphodiesterase activities. J Chromatogr B Analyt Technol Biomed Life Sci 911:162-9.
149. Lee SY, Muller CE. (2014). Large-volume sample stacking with polarity switching for monitoring of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) reactions by capillary electrophoresis. Electrophoresis 35:855-63.
150. Lehto MT, Sharom FJ. (1998). Release of the glycosylphosphatidylinositol- anchored enzyme ecto-50-nucleotidase by phospholipase C: catalytic activation and modulation by the lipid bilayer. Biochem J 332:101-9.
151. Lohman AW, Billaud M, Isakson BE. (2012). Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovasc Res 95: 269-80.
152. Loukovaara S, Sahanne S, Jalkanen S, et al. (2014). Increased intravitreal adenosine 50-triphosphate, adenosine 50-diphosphate and adenosine 50- monophosphate levels in patients with proliferative diabetic retinopathy. Acta Ophthalmol. doi: 10.1111/aos.12507 [in press].
153. Mackenzie NC, Huesa C, Rutsch F, et al. (2012). New insights into NPP1 function: lessons from clinical and animal studies. Bone 51:961-8.
154. Mahamed DA, Mills JH, Egan CE, et al. (2012). CD73-generated adenosine facilitates Toxoplasma gondii differentiation to long-lived tissue cysts in the central nervous system. Proc Natl Acad Sci USA 109:16312-17.
155. Maksimow M, Kyhäla L, Nieminen A, et al. (2014). Early prediction of persistent organ failure by soluble CD73 in patients with acute pancreatitis. Crit Care Med 42:2556-64.
156. Masse K, Bhamra S, Eason R, et al. (2007). Purine-mediated signalling triggers eye development. Nature 449:1058-62.
157. Masse K, Dale N. (2012). Purines as potential morphogens during embryonic development. Purinergic Signal 8:503-21.
158. Mercier N, Kiviniemi TO, Saraste A, et al. (2012). Impaired ATPinduced coronary blood flow and diminished aortic NTPDase activity precede lesion formation in apolipoprotein E-deficient mice. Am J Pathol 180:419-28.
159. Mi T, Abbasi S, Zhang H, et al. (2008). Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 118:1491-501.
160. Michaud M, Martins I, Sukkurwala AQ, et al. (2011). Autophagydependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334:1573-7.
161. Millan J. (2006a). Alkaline phosphatases. Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal 2:335-41.
162. Millan JL. (2006b). Mammalian alkaline phosphatases: from biology to application in medicine and biotechnology. Weinheim: Wiley-VCH Verlag GmbH & Co.
163. Mizumoto N, Kumamoto T, Robson SC, et al. (2002). CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med 8: 358-65.
164. Moolenaar WH, Perrakis A. (2011). Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol 12: 674-9.
165. Moriwaki Y, Yamamoto T, Higashino K. (1999). Enzymes involved in purine metabolism -a review of histochemical localization and functional implications. Histol Histopathol 14:1321-40.
166. Nakamachi Y, Koshiba M, Nakazawa T, et al. (2003). Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum 48:668-74.
167. Narisawa S, Huang L, Iwasaki A, et al. (2003). Accelerated fat absorption in intestinal alkaline phosphatase knockout mice. Mol Cell Biol 23:7525-30.
168. Niemela J, Ifergan I, Yegutkin GG, et al. (2008). IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol 38:2718-26.
169. Norman GA, Follett MJ, Hector DA. (1974). Quantitative thin-layer chromatography of ATP and the products of its degradation in meat tissue. J Chromatogr 90:105-11.
170. Ohta M, Toyama K, Gutterman DD, et al. (2013). Ecto-50-nucleotidase, CD73, is an endothelium-derived hyperpolarizing factor synthase. Arterioscler Thromb Vasc Biol 33:629-36.
171. Okawa A, Nakamura I, Goto S, et al. (1998). Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 19:271-3.
172. Pan J, Sun LC, Tao YF, et al. (2011). ATP synthase ecto-alphasubunit: a novel therapeutic target for breast cancer. J Transl Med 9: 211. doi: 10.1186/1479-5876-9-211.
173. Panayiotou C, Solaroli N, Karlsson A. (2014). The many isoforms of human adenylate kinases. Int J Biochem Cell Biol 49C:75-83.
174. Pannicke U, Honig M, Hess I, et al. (2009). Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nat Genet 41:101-5.
175. Parks RE, Agarwal RP. (1973). Nucleoside diphosphokinases. In: Boyer PD, ed. Enzymes. New York: Academic Press, 307-33.
176. Pearson JD. (1985). Ectonucleotidases: measurement of activities and use of inhibitors. In: Paton DM, ed. Methods in pharmacology. New York: Plenum Press, 83-107.
177. Pearson JD, Carleton JS, Gordon JL. (1980). Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smoothmuscle cells in culture. Biochem J 190:421-9.
178. Pelegrin P, Surprenant A. (2009). Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J 28:2114-27.
179. Pellegatti P, Raffaghello L, Bianchi G, et al. (2008). Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 3:e2599.
180. Pettengill M, Robson S, Tresenriter M, et al. (2013). Soluble ecto-50- nucleotidase (50-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine. J Biol Chem 288:27315-26.
181. Picher M, Boucher RC. (2003). Human Airway Ecto-adenylate Kinase. A mechanism to propagate atp signaling on airway surfaces. J Biol Chem 278:11256-64.
182. Picher M, Burch LH, Hirsh AJ, et al. (2003). Ecto 50-nucleotidase and nonspecific alkaline phosphatase. Two AMP- hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278: 13468-79.
183. Pike AF, Kramer NI, Blaauboer BJ, et al. (2013). A novel hypothesis for an alkaline phosphatase 'rescue' mechanism in the hepatic acute phase immune response. Biochim Biophys Acta 1832:2044-56.
184. Pinsky DJ, Broekman MJ, Peschon JJ, et al. (2002). Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 109:1031-40.
185. Plesner L. (1995). Ecto-ATPases: identities and functions. Int Rev Cytol 158:141-214.
186. Prosdocimo DA, Douglas DC, Romani AM, et al. (2009). Autocrine ATP release coupled to extracellular pyrophosphate accumulation in vascular smooth muscle cells. Am J Physiol Cell Physiol 296: C828-39.
187. Pull I, McIlwain H. (1972). Metabolism of (14 C)adenine and derivatives by cerebral tissues, superfused and electrically stimulated. Biochem J 126:965-73.
188. Quintero IB, Araujo CL, Pulkka AE, et al. (2007). Prostatic acid phosphatase is not a prostate specific target. Cancer Res 67:6549-54.
189. Quintero IB, Herrala AM, Araujo CL, et al. (2013). Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma. PLoS One 8:e73072.
190. Ralevic V, Burnstock G. (1998). Receptors for purines and pyrimidines. Pharmacol Rev 50:413-92.
191. Robson SC, Sevigny J, Zimmermann H. (2006). The E-NTPDase family of ectonucleotidases: structure function relationship and pathophysiological significance. Purinergic Signal 2:409-30.
192. Robson SC, Wu Y, Sun X, et al. (2005). Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 31:217-33.
193. Ruan Q, Chen Y, Gratton E, et al. (2002). Cellular characterization of adenylate kinase and its isoform: two-photon excitation fluorescence imaging and fluorescence correlation spectroscopy. Biophys J 83: 3177-87.
194. Rutsch F, Nitschke Y, Terkeltaub R. (2011). Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res 109: 578-92.
195. Rutsch F, Ruf N, Vaingankar S, et al. (2003). Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34:379-81.
196. Sachsenmeier KF, Hay C, Brand E, et al. (2012). Development of a novel ectonucleotidase assay suitable for high-throughput screening. J Biomol Screen 17:993-8.
197. Sansom FM, Robson SC, Hartland EL. (2008). Possible effects of microbial ecto-nucleoside triphosphate diphosphohydrolases on hostpathogen interactions. Microbiol Mol Biol Rev 72:765-81.
198. Sauer AV, Brigida I, Carriglio N, et al. (2012). Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood 119:1428-39.
199. Schwiebert EM, Zsembery A. (2003). Extracellular ATP as a signaling molecule for epithelial cells. Biochim Biophys Acta 1615:7-32.
200. Scotet E, Martinez LO, Grant E, et al. (2005). Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22: 71-80.
201. Sevigny J, Sundberg C, Braun N, et al. (2002). Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 99:2801-9.
202. Sorensen CE, Amstrup J, Rasmussen HN, et al. (2003). Rat pancreas secretes particulate ecto-nucleotidase CD39. J Physiol 551:881-92.
203. Sowa NA, Taylor-Blake B, Zylka MJ. (2010). Ecto-50-nucleotidase (CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive circuits. J Neurosci 30:2235-44.
204. Spychala J. (2000). Tumor-promoting functions of adenosine. Pharmacol Ther 87:161-73.
205. St Hilaire C, Ziegler SG, Markello TC, et al. (2011). NT5E mutations and arterial calcifications. N Engl J Med 364:432-42.
206. Stagg J, Beavis PA, Divisekera U, et al. (2012). CD73-deficient mice are resistant to carcinogenesis. Cancer Res 72:2190-6.
207. Stagg J, Smyth MJ. (2010). Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29:5346-58.
208. Stefan C, Jansen S, Bollen M. (2005). NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 30:542-50.
209. Stefan C, Jansen S, Bollen M. (2006). Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic Signal 2: 361-70.
210. Strater N. (2006). Ecto-50-nucleotidase: Structure function relationships. Purinergic Signal 2:343-50.
211. Street SE, Kramer NJ, Walsh PL, et al. (2013). Tissue-nonspecific alkaline phosphatase acts redundantly with pap and nt5e to generate adenosine in the dorsal spinal cord. J Neurosci 33:11314-22.
212. Strehler BL, Totter JR. (1952). Firefly luminescence in the study of energy transfer mechanisms. I. Substrate and enzyme determination. Arch Biochem Biophys 40:28-41.
213. Sunderman Jr FW,. (1990). The clinical biochemistry of 50-nucleotidase. Ann Clin Lab Sci 20:123-39.
214. Takedachi M, Qu D, Ebisuno Y, et al. (2008). CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J Immunol 180:6288-96.
215. Terkeltaub RA. (2001). Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 281:C1-11.
216. Todorov LD, Mihaylova-Todorova S, Westfall TD, et al. (1997). Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation. Nature 387:76-9.
217. Toro A, Paiva M, Ackerley C, et al. (2006). Intracellular delivery of purine nucleoside phosphorylase (PNP) fused to protein transduction domain corrects PNP deficiency in vitro. Cell Immunol 240:107-15.
218. van Meeteren LA, Moolenaar WH. (2007). Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 46:145-60.
219. van Meeteren LA, Ruurs P, Stortelers C, et al. (2006). Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26:5015-22.
220. Vandenbeuch A, Anderson CB, Parnes J, et al. (2013). Role of the ectonucleotidase NTPDase2 in taste bud function. Proc Natl Acad Sci USA 110:14789-94.
221. Vazquez MJ, Rodriguez B, Zapatero C, et al. (2003). Determination of phosphate in nanomolar range by an enzyme-coupling fluorescent method. Anal Biochem 320:292-8.
222. Villa-Bellosta R, Wang X, Millan JL, et al. (2011). Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J Physiol Heart Circ Physiol 301:H61-8.
223. Virtanen SS, Kukkonen-Macchi A, Vainio M, et al. (2014). Adenosine inhibits tumor cell invasion via receptor-independent mechanisms. Mol Cancer Res. doi: 10.1158/1541-7786.MCR-14-0302-T [in press].
224. Visovatti SH, Hyman MC, Bouis D, et al. (2012). Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. PLoS One 7:e40829.
225. Vollmayer P, Clair T, Goding JW, et al. (2003). Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/phosphodiesterases. Eur J Biochem 270:2971-8.
226. Wachstein M, Meisel E. (1957). Histochemistry of hepatic phosphatases of a physiologic pH; with special reference to the demonstration of bile canaliculi. Am J Clin Pathol 27:13-23.
227. Wall MJ, Dale N. (2013). Neuronal transporter and astrocytic ATP exocytosis underlie activity-dependent adenosine release in the hippocampus. J Physiol 591:3853-71.
228. Wen J, Xia Y. (2012). Adenosine signaling: good or bad in erectile function? Arterioscler Thromb Vasc Biol 32:845-50.
229. Yan H, Tsai M-D. (1999). Nucleoside monophosphate kinases: structure, mechanism, and substrate specificity. Adv Enzymol Relat Areas Mol Biol 73:103-34.
230. Yegutkin G, Bodin P, Burnstock G. (2000). Effect of shear stress on the release of soluble ecto-enzymes ATPase and 50-nucleotidase along with endogenous ATP from vascular endothelial cells. Br J Pharmacol 129:921-6.
231. Yegutkin GG. (2008). Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783:673-94.
232. Yegutkin GG, Helenius M, Kaczmarek E, et al. (2011a). Chronic hypoxia impairs extracellular nucleotide metabolism and barrier function in pulmonary artery vasa vasorum endothelial cells. Angiogenesis 14:503-13.
233. Yegutkin GG, Henttinen T, Jalkanen S. (2001). Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions. FASEB J 15:251-60.
234. Yegutkin GG, Henttinen T, Samburski SS, et al. (2002). The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells. Biochem J 367:121-8.
235. Yegutkin GG, Hytonen J, Samburski SS, et al. (2010). Disordered lymphoid purine metabolism contributes to the pathogenesis of persistent Borrelia garinii infection in mice. J Immunol 184:5112-20.
236. Yegutkin GG, Marttila-Ichihara F, Karikoski M, et al. (2011b). Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 41:1231-41.
237. Yegutkin GG, Mikhailov A, Samburski SS, et al. (2006a). The detection of micromolar pericellular ATP pool on lymphocyte surface by using lymphoid ecto-adenylate kinase as intrinsic ATP sensor. Mol Biol Cell 17:3378-85.
238. Yegutkin GG, Samburski SS, Jalkanen S. (2003). Soluble purineconverting enzymes circulate in human blood and regulate extracellular ATP level via counteracting pyrophosphatase and phosphotransfer reactions. FASEB J 17:1328-30.
239. Yegutkin GG, Samburski SS, Jalkanen S, et al. (2006b). ATP-consuming and ATP-generating enzymes secreted by pancreas. J Biol Chem 281: 29441-7.
240. Yegutkin GG, Samburski SS, Mortensen SP, et al. (2007). Intravascular ADP and soluble nucleotidases contribute to acute prothrombotic state during vigorous exercise in humans. J Physiol 579:553-64.
241. Yegutkin GG, Wieringa B, Robson SC, et al. (2012). Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities. FASEB J 26:3875-83.
242. Yegutkin GG, Yakubovskii SM, Gatsko GG. (1993). Alteration of 50-nucleotidase properties in rat adipose and liver plasma membranes after 1 Gy whole-body gamma-irradiation. Int J Radiat Biol 63: 583-7.
243. Yokdang N, Tellez JD, Tian H, et al. (2011). A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling. Br J Cancer 104:1628-40.
244. Yoshida M, Muneyuki E, Hisabori T. (2001). ATP synthase -a marvellous rotary engine of the cell. Nat Rev Mol Cell Biol 2:669-77.
245. Young A, Mittal D, Stagg J, et al. (2014). Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov 4:879-88.
246. Zavialov AV, Engstrom A. (2005). Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 391:51-7.
247. Zavialov AV, Gracia E, Glaichenhaus N, et al. (2010a). Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 88:279-90.
248. Zavialov AV, Yu X, Spillmann D, et al. (2010b). Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem 285:12367-77.
249. Zebisch M, Baqi Y, Schafer P, et al. (2014). Crystal structure of NTPDase2 in complex with the sulfoanthraquinone inhibitor PSB- 071. J Struct Biol 185:336-41.
250. Zebisch M, Krauss M, Schafer P, et al. (2012). Crystallographic evidence for a domain motion in rat nucleoside triphosphate diphosphohydrolase (NTPDase) 1. J Mol Biol 415:288-306.
251. Zernecke A, Bidzhekov K, Ozuyaman B, et al. (2006). CD73/ecto-50- nucleotidase protects against vascular inflammation and neointima formation. Circulation 113:2120-7.
252. Zhou Q, Yang D, Ombrello AK, et al. (2014). Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370: 911-20.
253. Zhou Y, Murthy JN, Zeng D, et al. (2010). Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One 5: e9224.
254. Zhou Y, Xu Z, Yoon J. (2011). Fluorescent and colorimetric chemosensors for detection of nucleotides, FAD and NADH: highlighted research during 2004-2010. Chem Soc Rev 40:2222-35.
255. Zimmermann H. (1992). 50-Nucleotidase: molecular structure and functional aspects. Biochem J 285:345-65.
256. Zimmermann H. (1996). Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog Neurobiol 49: 589-618.
257. Zimmermann H. (2009). Prostatic acid phosphatase, a neglected ectonucleotidase. Purinergic Signal 5:273-5.
258. Zimmermann H, Zebisch M, Strater N. (2012). Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 8: 437-502.
259. Zylka MJ. (2011). Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 17:188-96.
260. Zylka MJ, Sowa NA, Taylor-Blake B, et al. (2008). Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 60:111-22.